The Ministry of Health and Community Protection has obligated pharmaceutical companies to add warnings to 16 drug bulletins, containing drug substances such as "gabapentin and pregabalin", which are used to treat seizures, nerve pain, and myocardial dysfunction syndrome, in a circular addressed to all health facilities, drug companies, practitioners and health care providers.

In a circular obtained by Emirates Today, the ministry clarified that serious breathing difficulties may occur in patients using gabapentin or pregabalin, especially for those with respiratory problems, and when gabapentinoids are released in conjunction with opiates and central nervous system depressants, such as benzodiazepine And the risk of infection is greater for the elderly.

In the circular, the ministry stated that producing companies should add warnings about the risk of respiratory depression to the internal leaflet of gabapentinouds medications, especially when used with opiates. The Ministry required medical care practitioners to dispel gabapentin at the lowest dose, and to monitor patients for symptoms of respiratory depression and anesthesia, especially when prescribed with opioids or other central nervous system inhibitors, such as benzodiazepines, and patients should seek immediate medical attention when symptoms indicating respiratory problems occur When using these medications.

The Ministry confirmed that these medications are registered with its drug administration, and that these medications are safe to use and have not been withdrawn from the market.

The list of drugs included 16 types: conventin produced by Eva Pharma, Gabalept produced by Micro Labs, Gabanet from Jordanian Pharma, Gabapentin fidia produced by Vidia Pharma SBA, Gabata from Kim Lab, Gabatrex from Al-Hikma Pharma, and Nervan and produced by Julphar, Nervz from New Pharma, Neuroplex from Tabuk, Lyrica from Pfizer, Nervalin from Tabuk, and Nervigen from NewPharma.

The list also included Neugabalin drugs produced by NewPharma, Pregadex from Spimaco Pharmaceuticals, Prex from Pharma Island, and Progaba from NewPharma.